Economic evaluation of Varicella vaccination: results of a systematic review

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
September 2013  Volume 9, Issue 9

Economic evaluation of Varicella vaccination: results of a systematic review
Brigid Unim, Rosella Saulle, Sara Boccalini, Cristina Taddei, Vega Ceccherini, Antonio Boccia, Paolo Bonanni and Giuseppe La Torre  Pages 1932 – 1942

The aim of the present study is to review the economic burden of varicella disease and the benefit of universal varicella vaccination in different settings pending its implementation in all Italian regions.

Materials and Methods
Research was conducted using PubMed, Scopus and ISI databases. Score quality and data extraction were performed for all included studies.

Twenty-three articles met the criteria: 15 cost-effectiveness, 8 cost-benefit and one cost-utility analysis. Varicella vaccination could save the society from €637,762 (infant strategy) to 53 million annually (combined infant and adolescent strategy). The median and the mean quality scores resulted in 91.8% and 85.4% respectively; 11 studies were considered of high quality and 12 of low quality.

The studies are favorable to the introduction of universal varicella vaccination in Italy, being cost saving and having a positive impact on morbidity. The quality score of the studies varied greatly: recent analyses were of comparable quality to older studies.